GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2023-05-08| Partnerships

Boehringer, Kinoxis Ink $181 Million Pact To Target Oxytocin Receptors

by Joy Lin
Share To

German drugmaker Boehringer Ingelheim is partnering with University of Sydney spinout Kinoxis Therapeutics to develop oxytocin-targeting treatments for people living with psychiatric disorders. 

The collaboration is estimated to be worth up to $181 million ($A273 million) in payments, while Kinoxis could reap royalties on potential product sales. It will also bring in significant funding for the University of Sydney’s School of Chemistry, School of Psychology, and the Brain and Mind Center that will be closely collaborating with Boehringer and Kinoxis. 

Related article: Boehringer to Leverage RetinAI’s AI Tech to Further Geographic Atrophy Research 

Small Molecules that Target Oxytocin Receptors

Kinoxis focuses on developing chemical compounds that target the oxytocin receptor. These compounds were developed under research led by Kinoxis co-founder Professor Michael Kassiou of the Drug Discovery Initiative and School of Chemistry. 

The therapeutic potential of these compounds are being evaluated by a team led by Kinoxis Chief Scientific Officer and co-founder Associate Professor Michael Bowen of the School of Psychology and Brain and Mind Center. 

“More than three million Australians suffer from illnesses that impair social functioning. The oxytocin receptors in the brain have emerged as an attractive drug target but they have been intractable with small molecules,” said Professor Kassiou.

“More than 10 years ago my group began investigating the chemistry and pharmacology relating to the oxytocin receptor. We have discovered several series of small molecules, now licensed to Kinoxis, that have allowed us to target the oxytocin receptor in ways not previously possible.” 

Kinoxis’ lead compound, KNX100, is currently enrolling patients in a Phase 1 trial for the management of opioid withdrawal symptoms. According to Kinoxis, KNX100 has shown promising preclinical results in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression. The drug has drawn attention from the US National Institutes of Health Helping to End Addiction Long-Term, or the NIH HEAL Initiative, which awarded $4.6 million over a four year span to Kinoxis to advance its preclinical and clinical development. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Pre-JPM 2025: The Quiet Deals You May Have Missed Before the Big Show
2025-01-16
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Boehringer to Leverage RetinAI’s AI Tech to Further Geographic Atrophy Research
2023-04-23
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top